Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
20 Cards in this Set
- Front
- Back
|
sirolimus |
specific lymphocyte-signaling inhibitors binds to FK binding protein (FKBP) blocks the molecular target of rapamycin (mTOR) receptor in the IL2 receptor signaling pathway, inhibit T-cell proliferation |
|
|
TNF- α neutralization |
anti-cytokine therapy Treats RA TNFa secreted by macrophages, mast cells, activated TH cells. RA TNFa secreted by activated macrophages in affected joint. |
|
|
Etanercept |
Soluble TNFa receptor dimer TNF ligand binding domain + Fc domain of IgG1 Binds and inactivatees TNFa can have mild to moderate erythema, pruritus, pain and swelling at site of injection |
|
|
Infliximab |
Chimeric anti-TNFa monoclonal antibody human FC and mouse variable region binds with high affinity to TNFa Tx for RA, crohn's dz, ulcerative colitis Hypersensitivity reaction can occur |
|
|
Adalimumab |
fully humanized recombined IgG1 against TNFa similar to infliximab with smaller risk of hypersensitivity All TNFa blocking agents can cause serious infections, sepsis, tuberculosis and fungal infection (opportunistic) |
|
|
TNFa neutralizing agents (3) |
Infliximab Adalimumab Etanercept |
|
|
anakinra |
interleukin-1 Receptor antagonist (IL-1Ra) Competitively inhibits IL1B (immune function) binding to receptor Lowers inflammatory reaction in RA adverse effect similar to TNF blocker, serious infection |
|
|
MAB |
against cell surface receptors expressed on malignant activated immune cells. Preferentially deplete receptors. Depletion of specific immune cells Adverse Effect: Antibody bind to T Cell receptor causing cytokine release before they are destroyed. |
|
|
Anti-thymocyte globulin (ATG) |
Polyclonal Antibodies injecting rabbits with human thymocytes target many epitopes on human T cells, target essentially all T cells For depletion of specific immune Cells Can cause cytokine release syndrome Development of antibodies against rabbit-specific epitopes |
|
|
OKT3 (muromonab-CD3) |
A type of MAB mouse monoclonal antibody against human CD3 CD3 expressed by both CD4 and CD8 T cell cause transient immunosuppression, T Cell level return to normal within a week of discontinuing use Can cause cytokine release syndrome Antibody against mouse |
|
|
rituximab |
a type of MAB anti-CD20 chimeric murine/human monoclonal CD20 found on B lymphocytes, rituximab result in B-cell depletion treats RA, B cells perpetuate inflammatory response. Rituximab used with methotrexate to treat RA thats refractory to TNFa inhibitor Also treats Non-Hodgkins |
|
|
Basiliximab |
A type of MAB Chimeric Anti-CD25, a IL-2 receptor CD25 ONLY on activated T cells, IL-2 binding allow clonal expansion. |
|
|
abatacept |
Inhibition of costimulation fully human recombinant fusion protein binds to B7 and keeps it from interacting with CD28. disrupts the activation pathway of T cells and causes antigen to make T cell become anergic |
|
|
belatacept |
Inhibition of costimulation Similar mechanism to abatacept only indicated for use in Epstein-Barr virus (EBV) seropositive patients because of the risk of post-transplant lymphoproliferative disorder |
|
|
natalizumab |
cell adhesion blockade blocks alpha-4 integrins critical to immune-cel1 adhesion treatment of multiple sclerosis and Crohn's disease several patients developed progressive multifocal leukoencephalopathy (PML) |
|
|
eculizumab |
Suppression of Complement Activation humanized monoclonal antibody against C5, late complement trigger protein that causes assembly of the MAC Treat paroxysmal nocturnal hemoglobinuria (PNH); decreases hemoglobinuria and the need for erythrocyte transfusions |
|
|
Ibalizumab |
MAB for CD4 down-modulates cell surface expression of CD4 andblocks binding of residual CD4 to MHC class II makes T cells anergic but does not deplete |
|
|
Alemtuzumab |
MAB against CD52 Present on mature B and T cells severely depletes T and B cells Tx for lymphocytic leukemia (-tu-) |
|
|
Bortezomib |
Proteasome inhibitor depletion of plasma cells tx for multiple myeloma |
|
|
tocilizumab |
anti-IL-6 Receptor MAB Prevents inflammatory effects of IL-6 For patient with high PRA (panel Reactive antibody) |
